在拒绝推辅助治疗后,高级口腔状细胞癌的瘤结果
Friedrich Mrosk1, Christian Doll1, Julia Scheer1
1Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Oral and Maxillofacial Surgery, Berlin, Germany.
拒绝辅助治疗 (AT) 的晚期口腔平细胞癌 (OSCC) 患者的疾病复发率显著增加,生存率降低. 这凸显了AT在改善OSCC患者的瘤结果方面的重要性.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 手术瘤学手术瘤学
背景情况:
- 先进的口腔状细胞癌 (OSCC) 治疗往往涉及辅助疗法 (AT) 切除后.
- 对于那些拒绝推的AT的晚期OSCC患者的瘤结局存在有限的数据.
- 了解AT拒绝后的结果对于临床决策和患者咨询至关重要.
研究的目的:
- 为了比较AT拒绝AT的高级OSCC患者的生存率和疾病复发率与完成AT的患者.
- 为了确定与拒绝AT的患者的较差结果相关的因素.
主要方法:
- 一个单一中心的回顾性匹配队列研究.
- 根据瘤分期 (UICC) 匹配了82名晚期OSCC患者 (41人拒绝AT,41人完成AT).
- 主要结局:整体存活率 (OS) 和无复发存活率 (RFS).
主要成果:
- 拒绝AT的患者的疾病复发率显著更高 (61.0%对26.8%),2年后的生存率 (72.7%对88.6%) 和RFS (39.1%对74.2%) 较低.
- 拒绝AT与4.26倍更高的复发几率有关.
- 在拒绝AT的患者中,更糟糕的OS与女性性别,pT1-2和pN1+有关;更糟糕的RFS与女性性别,先进的T,高淋巴结产量和低淋巴结比率有关.
结论:
- 晚期OSCC中拒绝辅助治疗与明显更糟糕的瘤结局有关,包括复发率增加和生存率降低.
- 该研究提供了关键数据,以支持临床医生在咨询患者时考虑拒绝或撤回AT.
- 识别AT拒绝患者的预后因素可以帮助个性化风险评估和管理策略.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
相关概念视频
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
